drugset / Trial / NCT03013881

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers

NCT03013881

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single-dose of UB-921 in healthy male volunteers.

Timeline

Start
2018-03-05
Primary completion
2018-10-08
Completion
2019-04-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Trastuzumab Monoclonal antibody 6 mg/kg Intravenous
Subject UB-921 Unknown 2 mg/kg Intravenous
Subject UB-921 Unknown 6 mg/kg Intravenous
Subject UB-921 Unknown 8 mg/kg Intravenous

Indications